Sentinel Lymph Node Biopsy for Cutaneous Melanoma
Open Access
- 1 August 2005
- journal article
- research article
- Published by American Medical Association (AMA) in Archives of Dermatology
- Vol. 141 (8), 1016-1022
- https://doi.org/10.1001/archderm.141.8.1016
Abstract
The incidence of melanoma is rising more rapidly than that of any other cancer.1 The lifetime incidence of melanoma in the United States is 1 in 68.2 Although all stages of melanoma are increasing in incidence, earlier diagnosis has contributed to an increasing proportion of thin, early-stage melanoma with greater likelihood for cure.3Keywords
This publication has 48 references indexed in Scilit:
- The Melanoma Epidemic: Res Ipsa LoquiturThe Oncologist, 2003
- Current management of melanoma: Benefits of surgical staging and adjuvant therapyJournal of Surgical Oncology, 2003
- New TNM melanoma staging system: Linking biology and natural history to clinical outcomesSeminars in Surgical Oncology, 2003
- Prognostic Factors Analysis of 17,600 Melanoma Patients: Validation of the American Joint Committee on Cancer Melanoma Staging SystemJournal of Clinical Oncology, 2001
- Cost Analysis of Sentinel Lymph Node Biopsy as an Alternative to Elective Lymph Node Dissection in Patients with Malignant MelanomaSurgical Oncology Clinics of North America, 1999
- Multi-Institutional Melanoma Lymphatic Mapping Experience: The Prognostic Value of Sentinel Lymph Node Status in 612 Stage I or II Melanoma PatientsJournal of Clinical Oncology, 1999
- The incidence of malignant melanoma in the United States: Issues as we approach the 21st centuryJournal of the American Academy of Dermatology, 1996
- Sentinel lymph node status as an indicator of the presence of metastatic melanoma in regional lymph nodesMelanoma Research, 1995
- The Orderly Progression of Melanoma Nodal MetastasesAnnals of Surgery, 1994
- Technical Details of Intraoperative Lymphatic Mapping for Early Stage MelanomaArchives of Surgery, 1992